Education
About Us
Working with TipRanks
Follow Us
AnaptysBio (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
$45.68
-$0.23(-1.55%)
At close: 4:00 PM EST
$45.68
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$12.21 - $52.47
Previous CloseN/A
Volume154.73K
Average Volume (3M)460.98K
Market Cap
$1.26B
Enterprise Value$986.03M
Total Cash (Recent Filing)$248.96M
Total Debt (Recent Filing)$346.45M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 09, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,688,470
10 Day Avg. Volume637,227
30 Day Avg. Volume460,983
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)5.30
Price to Sales (P/S)4.12
P/FCF Ratio-2.77
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue5.82
Enterprise Value/Gross Profit59.88
Enterprise Value/Ebitda-215.76
Forecast
1Y Price Target
$71.25Price Target Upside55.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.06
Revenue Forecast (FY)$120.73M
Bulls Say, Bears Say
Bulls Say
Corporate StrategyPlan to separate into a royalty vehicle and a biopharma company could unlock valuation by isolating high-value Jemperli royalties from development risk and attracting investors focused on steady cash flows.
Novel Mechanism / Asset DifferentiationANB033's potent inhibition of key cytokines and notable reduction in specific immune cell activity suggest a differentiated mechanism that may offer advantages over peer assets.
Rheumatoid Arthritis Clinical ProgressStrong Phase 2 results in rheumatoid arthritis showing durable clinical responses and a clean safety profile support partnering interest and advancement with non-dilutive capital.
Bears Say
Legal Litigation RiskAn unfavorable litigation outcome could remove or limit rights to Jemperli, reducing expected royalty income and increasing legal costs, which would weigh on the stock.
Royalty Revenue RiskIf the commercial partner obtains broader license terms, royalty rates and milestone payments could be cut substantially, materially lowering future royalty cash flows tied to Jemperli.
Ulcerative Colitis Clinical RiskFailure of the Phase 2 ulcerative colitis study would suggest T cell targeting may not drive disease response in that indication, undermining rosnilimab's potential and reducing clinical upside.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $12.21 and its highest was $52.47 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.26B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is Mar 09, 2026 which is in 49 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on Nov 04, 2025. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of -$1.214 by $1.734.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is 0.89.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 27,688,470 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of $0.52 in its last earnings report, beating expectations of -$1.214. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.25 (55.98% Upside)
$71.25 (55.98% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $723.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
203.92%
12-Months-Change
Fundamentals
Return on Equity
-308.02%
Trailing 12-Months
Asset Growth
-28.44%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$71.25
▲(55.98% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
Currently, No data available
---